The value of plasma methylated Septin9 in monitoring the recurrence and metastasis of colorectal cancer after surgery_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

ZHAO Tuanjie ¹ , SU Yue ¹ , ZHANG Zhiliang ¹ , REN Chuncheng ¹ , LIU Liancheng ¹ , QI Shunli ² , CHEN Xilin ² ,  ZHANG Yuru ¹

1. Department of Colorectal Surgery, Beijing Anorectal Hospital (Beijing Erlonglu Hospital), Beijing 100120, P. R. China;
2. Department of Pathology, Beijing Anorectal Hospital (Beijing Erlonglu Hospital), Beijing 100120, P. R. China;

Corresponding?author：

ZHANG Yuru, Email: zhyr_11@163.com

Keywords：

colorectal cancer; methylated Septin9; postoperative surveillance; recurrence; metastasis

DOI：

10.7507/1007-9424.202108093

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the value of methylated Septin9 (mSEPT9) in the diagnosis and postoperative recurrence/metastasis monitoring of colorectal cancer. Methods A total of 76 patients with colorectal cancer who were hospitalized in Beijing Anorectal Hospital (Beijing Erlonglu Hospital) and positive for mSEPT9 before operation from January to December in 2020 were collected. Nineteen patients who were still positive for mSEPT9 at one week after operation were selected as the msept9 positive group, and 57 patients whose mSEPT9 became negative were selected as the msept9 negative group. The clinicopathological features and postoperative recurrence and metastasis of the two groups were analyzed and compared. Results There were significant differences in lymph node metastasis rate, vascular or nerve infiltration and clinical staging between the mSEPT9 positive group and the mSEPT9 negative group (P=0.024, P=0.009, P=0.009). There was no significant difference in age, gender, tumor location, degree of tumor differentiation, and tumor invasion depth (T stage), P>0.05. Two patients in the mSEPT9 positive group had liver metastases after operation, and there were no cases of metastasis or recurrence in the mSEPT9 negative group (P=0.024). Conclusion The mSEPT9 can be used as a potential tumor marker for the diagnosis of colorectal cancer and the monitoring of postoperative treatment effect, and more attention should be paid to patients who are still positive for mSEPT9 after surgery.

Citation： ZHAO Tuanjie, SU Yue, ZHANG Zhiliang, REN Chuncheng, LIU Liancheng, QI Shunli, CHEN Xilin, ZHANG Yuru. The value of plasma methylated Septin9 in monitoring the recurrence and metastasis of colorectal cancer after surgery. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2022, 29(6): 743-747. doi: 10.7507/1007-9424.202108093 Copy

1.	中華人民共和國衛生和計劃生育委員會醫政醫管局, 中華醫學會腫瘤學分會. 中國結直腸癌診療規范(2017年版). 中華外科雜志, 2018, 56(4): 241-258.
2.	van der Stok EP, Spaander M, Grünhagen DJ, et al. Surveillance after curative treatment for colorectal cancer. Nat Rev Clin Oncol, 2017, 14(5): 297-315.
3.	Rockall TA, McDonald PJ. Carcinoembryonic antigen: its value in the follow-up of patients with colorectal cancer. Int J Colorectal Dis, 1999, 14(1): 73-77.
4.	余智操, 吳晉, 張瓊, 等. SEPT 9基因與惡性腫瘤關系的研究進展. 現代腫瘤醫學. 2018. 26(2): 297-301.
5.	Tham C, Chew M, Soong R, et al. Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer. Cancer, 2014, 120(20): 3131-3141.
6.	Su XL, Wang YF, Li SJ, et al. High methylation of the SEPT9 gene in Chinese colorectal cancer patients. Genet Mol Res, 2014, 13(2): 2513-2520.
7.	Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut, 2014, 63(2): 317-325.
8.	Jin P, Kang Q, Wang X, et al. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm. J Gastroenterol Hepatol, 2015, 30(5): 830-833.
9.	Wu D, Zhou G, Jin P, et al. Detection of colorectal cancer using a simplified SEPT9 gene methylation assay is a reliable method for opportunistic screening. J Mol Diagn, 2016, 18(4): 535-545.
10.	鄭民華, 馮波, 馬君俊, 等. 腹腔鏡結直腸癌根治術操作指南(2018版). 中華消化外科雜志, 2018, 17(9): 877-885.
11.	Benson AB, Venook AP, Al-Hawary MM, et al. NCCN Guidelines Insights: Rectal Cancer, Version 6. 2020. J Natl Compr Canc Netw, 2020, 18(7): 806-815.
12.	趙媛, 陳四明, 蔣益蘭, 等. Septin-9基因甲基化檢測對結直腸癌診斷價值的meta分析. 中國醫師雜志, 2020, 22(6): 852-856.
13.	Fu B, Yan P, Zhang S, et al. Cell-free circulating methylated SEPT9 for noninvasive diagnosis and monitoring of colorectal cancer. Dis Markers. 2018, 2018: 6437104. doi: doi: 10.1155/2018/6437104.
14.	Yang X, Xu ZJ, Chen X, et al. Clinical value of preoperative methylated septin 9 in Chinese colorectal cancer patients. World J Gastroenterol, 2019, 25(17): 2099-2109.
15.	Molnár B, Tóth K, Barták BK, et al. Plasma methylated septin 9: a colorectal cancer screening marker. Expert Rev Mol Diagn, 2015, 15(2): 171-184.
16.	Xie L, Jiang X, Li Q, et al. Diagnostic value of methylated Septin9 for colorectal cancer detection. Front Oncol, 2018, 8: 247. doi: 10.3389/fonc.2018.00247.
17.	Chen Y, Wang Z, Zhao G, et al. Performance of a novel blood-based early colorectal cancer screening assay in remaining serum after the blood biochemical test. Dis Markers, 2019, 2019: 5232780. doi: doi: 10.1155/2019/5232780.
18.	康倩, 金鵬, 楊浪, 等. 外周血游離DNA中Septin9基因甲基化在結直腸癌篩查中的意義. 中華醫學雜志, 2014, 94(48): 3839-3841.
19.	李士杰, 劉艷剛, 王警, 等. 外周血Septin9基因甲基化檢測在結直腸癌篩查中的應用. 中國普通外科雜志, 2015, 24(12): 1756-1760.
20.	吳東, 楊紅, 李玥, 等. 外周血甲基化Septin9基因聯合糞便免疫化學試驗對專科門診患者結直腸癌和腺瘤的篩查. 中華消化雜志, 2016, 36(2): 107-112.
21.	堵一喬, 胡婷婷, 王文惠, 等. 結直腸癌患者血漿SEPT9基因甲基化檢測的研究. 中華檢驗醫學雜志, 2018, 41(5): 395-398.
22.	Hu J, Hu B, Gui YC, et al. Diagnostic value and clinical significance of methylated SEPT9 for colorectal cancer: a meta-analysis. Med Sci Monit, 2019, 25: 5813-5822.
23.	Ma ZY, Law WL, Ng EKO, et al. Methylated Septin 9 and carcinoembryonic antigen for serological diagnosis and monitoring of patients with colorectal cancer after surgery. Sci Rep, 2019, 9(1): 10326. doi: 10.1038/s41598-019-46876-4.
24.	Song L, Guo S, Wang J, et al. The blood mSEPT9 is capable of assessing the surgical therapeutic effect and the prognosis of colorectal cancer. Biomark Med, 2018, 12(9): 961-973.
25.	祝志強. 血漿Septin9基因甲基化對結直腸癌診斷、手術療效評估及復發監測的臨床應用價值, 新疆醫科大學, 2020.

1. 中華人民共和國衛生和計劃生育委員會醫政醫管局, 中華醫學會腫瘤學分會. 中國結直腸癌診療規范(2017年版). 中華外科雜志, 2018, 56(4): 241-258.
2. van der Stok EP, Spaander M, Grünhagen DJ, et al. Surveillance after curative treatment for colorectal cancer. Nat Rev Clin Oncol, 2017, 14(5): 297-315.
3. Rockall TA, McDonald PJ. Carcinoembryonic antigen: its value in the follow-up of patients with colorectal cancer. Int J Colorectal Dis, 1999, 14(1): 73-77.
4. 余智操, 吳晉, 張瓊, 等. SEPT 9基因與惡性腫瘤關系的研究進展. 現代腫瘤醫學. 2018. 26(2): 297-301.
5. Tham C, Chew M, Soong R, et al. Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer. Cancer, 2014, 120(20): 3131-3141.
6. Su XL, Wang YF, Li SJ, et al. High methylation of the SEPT9 gene in Chinese colorectal cancer patients. Genet Mol Res, 2014, 13(2): 2513-2520.
7. Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut, 2014, 63(2): 317-325.
8. Jin P, Kang Q, Wang X, et al. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm. J Gastroenterol Hepatol, 2015, 30(5): 830-833.
9. Wu D, Zhou G, Jin P, et al. Detection of colorectal cancer using a simplified SEPT9 gene methylation assay is a reliable method for opportunistic screening. J Mol Diagn, 2016, 18(4): 535-545.
10. 鄭民華, 馮波, 馬君俊, 等. 腹腔鏡結直腸癌根治術操作指南(2018版). 中華消化外科雜志, 2018, 17(9): 877-885.
11. Benson AB, Venook AP, Al-Hawary MM, et al. NCCN Guidelines Insights: Rectal Cancer, Version 6. 2020. J Natl Compr Canc Netw, 2020, 18(7): 806-815.
12. 趙媛, 陳四明, 蔣益蘭, 等. Septin-9基因甲基化檢測對結直腸癌診斷價值的meta分析. 中國醫師雜志, 2020, 22(6): 852-856.
13. Fu B, Yan P, Zhang S, et al. Cell-free circulating methylated SEPT9 for noninvasive diagnosis and monitoring of colorectal cancer. Dis Markers. 2018, 2018: 6437104. doi: doi: 10.1155/2018/6437104.
14. Yang X, Xu ZJ, Chen X, et al. Clinical value of preoperative methylated septin 9 in Chinese colorectal cancer patients. World J Gastroenterol, 2019, 25(17): 2099-2109.
15. Molnár B, Tóth K, Barták BK, et al. Plasma methylated septin 9: a colorectal cancer screening marker. Expert Rev Mol Diagn, 2015, 15(2): 171-184.
16. Xie L, Jiang X, Li Q, et al. Diagnostic value of methylated Septin9 for colorectal cancer detection. Front Oncol, 2018, 8: 247. doi: 10.3389/fonc.2018.00247.
17. Chen Y, Wang Z, Zhao G, et al. Performance of a novel blood-based early colorectal cancer screening assay in remaining serum after the blood biochemical test. Dis Markers, 2019, 2019: 5232780. doi: doi: 10.1155/2019/5232780.
18. 康倩, 金鵬, 楊浪, 等. 外周血游離DNA中Septin9基因甲基化在結直腸癌篩查中的意義. 中華醫學雜志, 2014, 94(48): 3839-3841.
19. 李士杰, 劉艷剛, 王警, 等. 外周血Septin9基因甲基化檢測在結直腸癌篩查中的應用. 中國普通外科雜志, 2015, 24(12): 1756-1760.
20. 吳東, 楊紅, 李玥, 等. 外周血甲基化Septin9基因聯合糞便免疫化學試驗對專科門診患者結直腸癌和腺瘤的篩查. 中華消化雜志, 2016, 36(2): 107-112.
21. 堵一喬, 胡婷婷, 王文惠, 等. 結直腸癌患者血漿SEPT9基因甲基化檢測的研究. 中華檢驗醫學雜志, 2018, 41(5): 395-398.
22. Hu J, Hu B, Gui YC, et al. Diagnostic value and clinical significance of methylated SEPT9 for colorectal cancer: a meta-analysis. Med Sci Monit, 2019, 25: 5813-5822.
23. Ma ZY, Law WL, Ng EKO, et al. Methylated Septin 9 and carcinoembryonic antigen for serological diagnosis and monitoring of patients with colorectal cancer after surgery. Sci Rep, 2019, 9(1): 10326. doi: 10.1038/s41598-019-46876-4.
24. Song L, Guo S, Wang J, et al. The blood mSEPT9 is capable of assessing the surgical therapeutic effect and the prognosis of colorectal cancer. Biomark Med, 2018, 12(9): 961-973.
25. 祝志強. 血漿Septin9基因甲基化對結直腸癌診斷、手術療效評估及復發監測的臨床應用價值, 新疆醫科大學, 2020.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

The value of plasma methylated Septin9 in monitoring the recurrence and metastasis of colorectal cancer after surgery

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content